GNE-9605
10mM in DMSO
- Product Code: 190293
CAS:
1536200-31-3
| Molecular Weight: | 449.83 g./mol | Molecular Formula: | C₁₇H₂₀ClF₄N₇O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
GNE-9605 is a potent and selective covalent inhibitor targeting the KRAS G12C mutant protein, which is commonly found in certain cancers such as non-small cell lung cancer (NSCLC) and colorectal cancer. It functions by irreversibly binding to the mutated cysteine residue in the KRAS G12C protein, locking it in an inactive state and thereby suppressing downstream signaling pathways that drive tumor growth. This compound has shown strong antitumor activity in preclinical models, particularly in tumors dependent on KRAS G12C signaling. Due to its high selectivity and favorable pharmacokinetic profile, GNE-9605 serves as a valuable tool compound in cancer research and has contributed to the development of clinical-stage KRAS inhibitors. It is primarily used in laboratory settings to study KRAS pathway inhibition, resistance mechanisms, and combination therapies with other oncology agents such as immune checkpoint inhibitors or SHP2 inhibitors.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿7,200.00 |
+
-
|
GNE-9605
GNE-9605 is a potent and selective covalent inhibitor targeting the KRAS G12C mutant protein, which is commonly found in certain cancers such as non-small cell lung cancer (NSCLC) and colorectal cancer. It functions by irreversibly binding to the mutated cysteine residue in the KRAS G12C protein, locking it in an inactive state and thereby suppressing downstream signaling pathways that drive tumor growth. This compound has shown strong antitumor activity in preclinical models, particularly in tumors dependent on KRAS G12C signaling. Due to its high selectivity and favorable pharmacokinetic profile, GNE-9605 serves as a valuable tool compound in cancer research and has contributed to the development of clinical-stage KRAS inhibitors. It is primarily used in laboratory settings to study KRAS pathway inhibition, resistance mechanisms, and combination therapies with other oncology agents such as immune checkpoint inhibitors or SHP2 inhibitors.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :